Code System: CDCNHSN
The CDCNHSN code system is highly specialized to meet the needs of NHSN surveillance reporting, is undergoing changes, and is not recommended for creating value sets to be used outside of NHSN.
OID: 2.16.840.1.113883.6.277
Name: NHSN Surveillance System Codes (CDCNHSN)
Definition: A set of healthcare surveillance vocabulary concepts and associated identifiers intended solely for data submissions to the National Healthcare Safety Network (NHSN). Other uses are not recommended.
Version: 2020-11
| Code | Description |
|---|---|
| 2350-2 | A new antimicrobial agent(s) is started, and is continued for >=4 days |
| 2105-5 | Abdominal aortic aneurysm repair |
| 2107-1 | Abdominal hysterectomy |
| 2118-8 | Abdominal surgery |
| 1309-4 | Active surgical site infection (SSI) detection method |
| 1871-3 | Active surveillance testing (AST) eligible patients |
| 3193-0 | Active surveillance testing (AST) organism monitored |
| 1957-0 | Acute onset of diarrhea (liquid stools for >12 hours) |
| 1971-1 | Acute pain, swelling, or tenderness of testes, epididymis, or prostate |
| 1510-7 | Admission (during the stay in which the surgery was performed) |
| 1652-7 | Admitting inpatient facility |
| 2368-9 | Adult students or trainees and volunteers |
| 2301-0 | All patients |
| 1965-3 | Allogeneic hematopoietic stem cell transplant (allo-SCT) with diarrhea |
| 1964-6 | Allogeneic hematopoietic stem cell transplant (allo-SCT) with grade >=3 gastrointestinal graft-versus-host disease (GI GVHD) |
| 1205-4 | Anterior and posterior |
| 6140-8 | Antimicrobial-coated catheter used |
| 1959-6 | Apnea, tachypnea, nasal flaring with retraction of chest wall or grunting |
| 2108-9 | Appendix surgery |
| 1623-8 | Arterial or venous infection |
| 2402-6 | Asymptomatic bacteremic UTI (ABUTI) |
| 1101-5 | Atlas-axis |
| 1102-3 | Atlas-axis/Cervical |
| 3061-9 | Atrial lines (right and left) |
| 1651-9 | Attending physician other than surgeon |
| 1820-0 | avibactam / ceftazidime |
| 2037-0 | Bacterial isolate tested for carbapenemase |
| 2513-0 | Bilateral infiltrates on chest x-ray |
| 2109-7 | Bile duct, liver or pancreatic surgery |
| 3302-7 | Birth weight 1001-1500 grams |
| 3303-5 | Birth weight 1501-2500 grams |
| 3301-9 | Birth weight 751-1000 grams |
| 3304-3 | Birth weight over 2500 grams |
| 3300-1 | Birth weight under 750 grams |
| 1902-6 | Blood culture not done or no organisms detected in blood |
| 2500-7 | Blood product was implicated in the adverse reaction |
| 2339-0 | Blood sample collected for culture |
| 1798-8 | Bone or joint infection |
| 1908-3 | Bradycardia or tachycardia |
| 1601-4 | Breast abscess or mastitis |
| 2110-5 | Breast surgery |
| 1671-7 | Bronchitis or tracheitis |
| 1672-5 | Burn infection |
| 2308-5 | Buttonhole cannulation |
| 2029-7 | C. difficile primary testing method used most often for this quarter |
| 1795-4 | C. difficile-associated disease (CDAD) infection |
| 6122-6 | Cap |
| 2045-3 | Carba NP |
| 2049-5 | Carbapenemase type |
| 2111-3 | Cardiac surgery |
| 2114-7 | Carotid endarterectomy |
| 2501-5 | Case definition match |
| 1969-5 | Catheter-graft hybrid |
| 1818-4 | ceftolozane / tazobactam |
| 2031-3 | Cell cytotoxicity neutralization assay |
| 1002-5 | Central line |
| 3121-1 | Central line exchanged over guidewire |
| 1006-6 | Central line including umbilical catheter |
| 3108-8 | Central line insertion practice (CLIP) |
| 2016-4 | CephR-Klebsiella |
| 1103-1 | Cervical |
| 1104-9 | Cervical/Dorsal/Dorsolumbar |
| 2115-4 | Cesarean section |
| 1603-0 | Clinical sepsis |
| 3195-5 | Clinical specialty |
| 2116-2 | Colon surgery |
| 1944-8 | Common commensal from >=2 blood cultures |
| 3070-0 | Common commensal from blood specimen(s) and antibiotics for >=5 days |
| 3072-6 | Common commensal from cerebrospinal fluid specimen and antibiotics for >=5 days |
| 2303-6 | Contamination |
| 2337-4 | Continuation of antimicrobial |
| 6130-9 | Contraindication type |
| 1325-0 | Cooperative infection prevention process between facilities |
| 2112-1 | Coronary artery bypass graft with both chest and donor site incisions |
| 2113-9 | Coronary artery bypass graft with chest incision only |
| 2117-0 | Craniotomy |
| 2018-0 | CRE-E. coli |
| 2019-8 | CRE-Enterobacter |
| 2017-2 | CRE-Klebsiella |
| 2352-5 | Criterion 1: positive culture from bronchoalveolar lavage without purulent respiratory secretions |
| 2351-1 | Criterion 1: positive culture from endotracheal aspirate without purulent respiratory secretions |
| 2353-3 | Criterion 1: positive culture from lung tissue without purulent respiratory secretions |
| 2354-1 | Criterion 1: positive culture from protected specimen brush without purulent respiratory secretions |
| 2358-0 | Criterion 2: organisms from bronchoalveolar lavage culture with purulent respiratory secretions |
| 2357-2 | Criterion 2: organisms from endotracheal aspirate culture with purulent respiratory secretions |
| 2359-8 | Criterion 2: organisms from lung tissue culture with purulent respiratory secretions |
| 2360-1 | Criterion 2: organisms from protected specimen brush culture with purulent respiratory secretions |
| 2356-4 | Criterion 2: organisms from sputum culture with purulent respiratory secretions |
| 2355-9 | Criterion 2: purulent respiratory secretions plus organism(s) |
| 2363-2 | Criterion 3: positive diagnostic test for Legionella species |
| 2364-0 | Criterion 3: positive diagnostic test for selected viral pathogens |
| 2362-4 | Criterion 3: positive test for lung histopathology |
| 2361-0 | Criterion 3: positive test for organism(s) identified from pleural fluid |
| 2516-3 | Criterion not otherwise specified |
| 2346-5 | Daily minimum FiO2 increase >=0.20 (20 points) for >=2 days |
| 2347-3 | Daily minimum PEEP increase >=3 cm H2O for >=2 days |
| 1815-0 | dalbavancin |
| 1373-0 | Date first admitted to facility |
| 1673-3 | Decubitus ulcer infection |
| 1604-8 | Deep incisional primary surgical site infection (SSI) |
| 1605-5 | Deep incisional secondary surgical site infection (SSI) |
| 1821-8 | delafloxacin |
| 2333-3 | Dialysis clinic |
| 2514-8 | Diffuse hemorrhage |
| 1674-1 | Disseminated infection |
| 1105-6 | Dorsal/Dorsolumbar |
| 1607-1 | Ear or mastoid infection (otitis externa, otitis media, otitis interna, mastoiditis) |
| 2366-3 | Employees (staff on facility payroll) |
| 2030-5 | Enzyme immunoassay (EIA) for toxin |
| 3057-7 | Epidermolysis bullosa during current admission |
| 1334-2 | Extremely preterm (<28 weeks) |
| 1608-9 | Eye infection, other than conjunctivitis |
| 6133-3 | Facility restrictions or safety concerns for chlorhexidine gluconate use in premature infants precludes its use |
| 3542-8 | Facility transfuses blood products treated with pathogen reduction technology |
| 4103-8 | Fellow |
| 1814-3 | fidaxomicin |
| 3498-3 | First discovery |
| 1938-0 | Fourfold rise in Legionella pneumophila antibody titer |
| 1935-6 | Fourfold rise in paired sera for pathogen |
| 1940-6 | Fungi or Pneumocystis carinii from lower respiratory tract specimen |
| 2119-6 | Gallbladder surgery |
| 2120-4 | Gastric surgery |
| 1609-7 | Gastrointestinal tract infection (esophagus, stomach, small and large bowel, and rectum) excluding gastroenteritis and appendicitis |
| 2033-9 | Glutamate dehydrogenase (GDH) antigen plus enzyme immunoassay (EIA) for toxin |
| 2035-4 | Glutamate dehydrogenase (GDH) plus enzyme immunoassay (EIA) for toxin, followed by nucleic acid amplification test (NAAT) for discrepant results |
| 2034-7 | Glutamate dehydrogenase (GDH) plus nucleic acid amplification test (NAAT) |
| 1929-9 | Greater than or equal to 2 positive urine cultures with >=100 cfu/ml of same uropathogen from non-voided specimen |
| 1931-5 | Greater than or equal to 2 positive urine cultures with >=100,000 cfu/ml with no more than 2 organisms |
| 1923-3 | Greater than or equal to 5% bronchoalveolar lavage cells with bacteria |
| 3109-6 | Hand hygiene |
| 2121-2 | Heart transplant |
| 3062-7 | Hemodialysis reliable outflow (HERO) catheter |
| 2543-7 | Hemovigilance module – monthly reporting denominator |
| 2106-3 | Herniorrhaphy |
| 2101-4 | Hip prosthesis |
| 1956-2 | Histopathologic exam with abscess formation or lung parenchyma invasion by fungal hyphae |
| 2332-5 | Hospital (on the day of or the day following admission) or Emergency Department |
| 1645-1 | Hospital transfer/admission |
| 1416-7 | HPRO: Hemi: Partial Primary |
| 1418-3 | HPRO: Hemi: Partial Revision |
| 1417-5 | HPRO: Hemi: Total Revision |
| 1421-7 | HPRO: Resurfacing: Partial Primary |
| 1422-5 | HPRO: Resurfacing: Partial Revision |
| 1419-1 | HPRO: Resurfacing: Total Primary |
| 1420-9 | HPRO: Resurfacing: Total Revision |
| 1415-9 | HPRO: Total: Partial Revision |
| 1413-4 | HPRO: Total: Total Primary |
| 1414-2 | HPRO: Total: Total Revision |
| 1924-0 | Imaging test evidence of infection |
| 2052-9 | Imipenemase |
| 2502-3 | Imputability of adverse reaction to transfusion |
| 2503-1 | Imputability of death to transfusion |
| 2307-7 | Imputability of positive blood culture to suspected source |
| 1967-9 | Incision deliberately opened or drained |
| 1675-8 | Infant pustulosis |
| 1656-8 | Infection first reported source |
| 3188-0 | Infection occurred post-procedure |
| 1797-0 | Infection of the ear, eyes, nose, or throat |
| 1237-7 | Infection present at time of surgery (PATOS) |
| 2344-2 | Infection-related ventilator-associated complication (IVAC) |
| 1610-5 | Intraabdominal infection, not specified elsewhere including gallbladder, bile ducts, liver (excluding viral hepatitis), spleen, pancreas, peritoneum, subphrenic or subdiaphragmatic space, or other intraabdominal tissue or area not specified elsewhere |
| 3063-5 | Intra-aortic balloon pump (IABP) device |
| 1611-3 | Intracranial infection (brain abscess, subdural or epidural infection, encephalitis) |
| 2306-9 | Intravenous injection of antifungal substance |
| 1819-2 | isavuconazonium |
| 2048-7 | Isolate tested positive for carbapenemase |
| 4100-4 | IV team |
| 1612-1 | Joint or bursa infection |
| 2122-0 | Kidney surgery |
| 2123-8 | Kidney transplant |
| 2050-3 | Klebsiella pneumoniae carbapenemase |
| 2124-6 | Knee prosthesis |
| 3055-1 | Known or suspected Munchausen syndrome by proxy during current admission |
| 1409-2 | KPRO: Hemi: Partial Primary |
| 1412-6 | KPRO: Hemi: Partial Revision |
| 1411-8 | KPRO: Hemi: Total Revision |
| 1408-4 | KPRO: Total: Partial Revision |
| 1406-8 | KPRO: Total: Total Primary |
| 1407-6 | KPRO: Total: Total Revision |
| 1613-9 | Laboratory-confirmed bloodstream infection |
| 2125-3 | Laminectomy |
| 6112-7 | Large sterile drape |
| 3002-3 | Last physical overnight location of patient immediately prior to arriving into facility |
| 1937-2 | Legionella pneumophila serogroup 1 antigens in urine |
| 2367-1 | Licensed independent practitioners: physicians, advanced practice nurses, and physician assistants |
| 2126-1 | Limb amputation |
| 2127-9 | Liver transplant |
| 1920-8 | Localized swelling |
| 2341-2 | Location of mechanical ventilation initiation |
| 2325-9 | Loss of vascular access |
| 1106-4 | Lumbar/Lumbosacral |
| 6110-1 | Mask |
| 1939-8 | Matching positive blood and sputum cultures with Candida species |
| 2010-7 | MDR-Acinetobacter |
| 2318-4 | MDRO or C. difficile infection |
| 4102-0 | Medical staff not otherwise specified |
| 1615-4 | Meningitis or ventriculitis |
| 2046-1 | Metallo-beta-lactamase gradient strip |
| 2047-9 | Metallo-beta-lactamase screen |
| 1336-7 | Moderate to late preterm (32 to <37 weeks) |
| 2044-6 | Modified Hodge test |
| 1942-2 | More than 15 colonies cultured from intravascular cannula tip using semi-quantitative culture method |
| 1792-1 | Multi-drug resistant organism (MDRO) infection |
| 1602-2 | Myocarditis or pericarditis |
| 2515-5 | Nausea/vomiting |
| 2128-7 | Neck surgery |
| 3066-8 | Neonatal Laboratory Confirmed Bloodstream Infection 1 (NLCBI 1) |
| 3067-6 | Neonatal Laboratory Confirmed Bloodstream Infection 2 (NLCBI 2) |
| 3068-4 | Neonatal Laboratory Confirmed Meningitis 1 (NLCM 1) |
| 3069-2 | Neonatal Laboratory Confirmed Meningitis 2 (NLCM 2) |
| 2336-6 | New antibiotic start |
| 2051-1 | New Delhi metallo-beta-lactamase |
| 1907-5 | New onset or change in sputum, increased secretions or increased suctioning |
| 1903-4 | New onset/change in sputum |
| 1904-2 | New onset/worsening cough, dyspnea, tachypnea |
| 1925-7 | New or progressive and persistent infiltrate |
| 2335-8 | New outpatient start or continuation of inpatient course |
| 1676-6 | Newborn circumcision infection |
| 3540-2 | No hemovigilance adverse reactions reported this month |
| 3541-0 | No hemovigilance incidents reported this month |
| 1311-0 | No location change |
| 3119-7 | No pathogen identified |
| 3064-3 | Non-accessed central line (not accessed nor inserted during the hospitalization) |
| 3189-8 | Non-autologous transplant |
| 2055-2 | Nonspecific carbapenemase activity |
| 2056-0 | Nonspecific metallo-beta-lactamase activity |
| 1119-7 | Non-tunneled (dialysis) |
| 1120-5 | Non-tunneled (other than dialysis) |
| 2103-0 | Not an NHSN operation |
| 1901-8 | Not cultured |
| 2032-1 | Nucleic acid amplification test (NAAT) |
| 2057-8 | Nucleic acid amplification test (NAAT) plus enzyme immunoassay (EIA), if NAAT positive (2-step algorithm) |
| 1862-2 | Number of admissions |
| 1831-7 | Number of admissions adjusted for C. difficile reporting |
| 1828-3 | Number of admissions adjusted for MDRO reporting (for inpatient location) |
| 1371-4 | Number of admissions on C. difficile treatment |
| 1641-0 | Number of admissions with an order for a prophylactic intravenous antibiotic that was administered on time |
| 1642-8 | Number of admissions with an order for a prophylactic intravenous antibiotic that was not administered on time |
| 1643-6 | Number of admissions with no order for a prophylactic intravenous antibiotic |
| 3499-1 | Number of adverse reactions |
| 1834-1 | Number of airway pressure release ventilation (APRV) days |
| 3533-7 | Number of aliquots transfused: Plasma: Apheresis: Psoralen-treated |
| 3536-0 | Number of aliquots transfused: Plasma: Apheresis: Riboflavin-treated |
| 3524-6 | Number of aliquots transfused: Plasma: Whole blood-derived: Psoralen-treated |
| 3527-9 | Number of aliquots transfused: Plasma: Whole blood-derived: Riboflavin-treated |
| 3424-9 | Number of aliquots transfused: Platelets: Apheresis: Irradiated |
| 3428-0 | Number of aliquots transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced |
| 3426-4 | Number of aliquots transfused: Platelets: Apheresis: Leukocyte-reduced |
| 3492-6 | Number of aliquots transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced |
| 3515-4 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated |
| 3569-1 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in plasma |
| 3572-5 | Number of aliquots transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution |
| 3518-8 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated |
| 3575-8 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in plasma |
| 3578-2 | Number of aliquots transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution |
| 3412-4 | Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated |
| 3416-5 | Number of aliquots transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced |
| 3414-0 | Number of aliquots transfused: Red Blood Cells: Apheresis: Leukocyte-reduced |
| 3479-3 | Number of aliquots transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced |
| 3560-0 | Number of aliquots transfused: Red Blood Cells: Apheresis: Riboflavin-treated |
| 3557-6 | Number of aliquots transfused: Red Blood Cells: Apheresis: S-303-treated |
| 3404-1 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated |
| 3408-2 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced |
| 3406-6 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced |
| 3472-8 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced |
| 3551-9 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated |
| 3548-5 | Number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303-treated |
| 2409-1 | Number of blood cultures performed |
| 1372-2 | Number of C. difficile treatment starts |
| 1833-3 | Number of central line days |
| 1854-9 | Number of central line days including umbilical catheter |
| 2310-1 | Number of chronic hemodialysis patients: fistula |
| 2312-7 | Number of chronic hemodialysis patients: graft |
| 2314-3 | Number of chronic hemodialysis patients: non-tunneled central line |
| 2315-0 | Number of chronic hemodialysis patients: other access device |
| 2313-5 | Number of chronic hemodialysis patients: tunneled central line |
| 3565-9 | Number of discards: Cryoprecipitate: Psoralen-treated |
| 3567-5 | Number of discards: Cryoprecipitate: Riboflavin-treated |
| 3534-5 | Number of discards: Plasma: Apheresis: Psoralen-treated |
| 3537-8 | Number of discards: Plasma: Apheresis: Riboflavin-treated |
| 3525-3 | Number of discards: Plasma: Whole blood-derived: Psoralen-treated |
| 3528-7 | Number of discards: Plasma: Whole blood-derived: Riboflavin-treated |
| 3494-2 | Number of discards: Platelets: Apheresis: Irradiated |
| 3496-7 | Number of discards: Platelets: Apheresis: Irradiated or leukocyte-reduced |
| 3495-9 | Number of discards: Platelets: Apheresis: Leukocyte-reduced |
| 3493-4 | Number of discards: Platelets: Apheresis: Not irradiated or leukocyte-reduced |
| 3516-2 | Number of discards: Platelets: Apheresis: Psoralen-treated |
| 3570-9 | Number of discards: Platelets: Apheresis: Psoralen-treated and in plasma |
| 3573-3 | Number of discards: Platelets: Apheresis: Psoralen-treated and in platelet additive solution |
| 3519-6 | Number of discards: Platelets: Apheresis: Riboflavin-treated |
| 3576-6 | Number of discards: Platelets: Apheresis: Riboflavin-treated and in plasma |
| 3579-0 | Number of discards: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution |
| 3487-6 | Number of discards: Platelets: Whole blood-derived: Irradiated |
| 3489-2 | Number of discards: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced |
| 3488-4 | Number of discards: Platelets: Whole blood-derived: Leukocyte-reduced |
| 3486-8 | Number of discards: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced |
| 3507-1 | Number of discards: Platelets: Whole blood-derived: Psoralen-treated |
| 3510-5 | Number of discards: Platelets: Whole blood-derived: Riboflavin-treated |
| 3481-9 | Number of discards: Red Blood Cells: Apheresis: Irradiated |
| 3483-5 | Number of discards: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced |
| 3482-7 | Number of discards: Red Blood Cells: Apheresis: Leukocyte-reduced |
| 3480-1 | Number of discards: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced |
| 3561-8 | Number of discards: Red Blood Cells: Apheresis: Riboflavin-treated |
| 3558-4 | Number of discards: Red Blood Cells: Apheresis: S-303-treated |
| 3474-4 | Number of discards: Red Blood Cells: Whole blood-derived: Irradiated |
| 3476-9 | Number of discards: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced |
| 3475-1 | Number of discards: Red Blood Cells: Whole blood-derived: Leukocyte-reduced |
| 3473-6 | Number of discards: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced |
| 3552-7 | Number of discards: Red Blood Cells: Whole blood-derived: Riboflavin-treated |
| 3549-3 | Number of discards: Red Blood Cells: Whole blood-derived: S-303-treated |
| 1863-0 | Number of encounters |
| 1832-5 | Number of encounters adjusted for C. difficile reporting |
| 1829-1 | Number of encounters adjusted for MDRO reporting |
| 1333-4 | Number of episodes of mechanical ventilation (EMV) days |
| 2311-9 | Number of fistula patients who undergo buttonhole cannulation |
| 1878-8 | Number of incident cases identified by monitoring (clinical positive) |
| 1826-7 | Number of new episodes of mechanical ventilation (EMV) |
| 1867-1 | Number of observations in which gown and gloves were used |
| 1864-8 | Number of observations in which hand hygiene was indicated |
| 1865-5 | Number of observations in which hand hygiene was performed |
| 1866-3 | Number of observations in which the use of gown and gloves was indicated |
| 1851-5 | Number of patient days |
| 1830-9 | Number of patient days adjusted for C. difficile reporting (for inpatient location) |
| 1827-5 | Number of patient days adjusted for MDRO reporting (for inpatient location) |
| 3436-3 | Number of patient samples collected for type and screen or crossmatch |
| 2525-4 | Number of patient-present days |
| 1872-1 | Number of patients eligible for monitoring at admission/transfer in |
| 1874-7 | Number of patients eligible for monitoring at discharge/transfer out |
| 1860-6 | Number of patients meeting high risk criteria and offered influenza vaccination but declining because of having medical contraindication |
| 1858-0 | Number of patients meeting high risk criteria and previously vaccinated for influenza during current influenza season |
| 1861-4 | Number of patients meeting high risk criteria and receiving vaccination during admission |
| 1856-4 | Number of patients meeting high risk criteria for influenza vaccination |
| 1859-8 | Number of patients meeting high risk criteria for influenza vaccination and offered influenza vaccination but declining for reasons other than medical contraindication |
| 1873-9 | Number of patients on which monitoring was performed at admission/transfer in |
| 1875-4 | Number of patients on which monitoring was performed at discharge/transfer out |
| 1857-2 | Number of patients previously vaccinated for influenza during current influenza season |
| 3306-8 | Number of permanent central line days |
| 1876-2 | Number of prevalent cases identified by monitoring (clinical positive) |
| 1877-0 | Number of prevalent cases previously known |
| 3305-0 | Number of temporary central line days |
| 2524-7 | Number of therapy days |
| 1889-5 | Number of total facility admissions (for inpatient location) |
| 1890-3 | Number of total facility encounters (for outpatient location) |
| 1888-7 | Number of total facility patient days (for inpatient location) |
| 3564-2 | Number of units transfused: Cryoprecipitate: Psoralen-treated |
| 3566-7 | Number of units transfused: Cryoprecipitate: Riboflavin-treated |
| 3532-9 | Number of units transfused: Plasma: Apheresis: Psoralen-treated |
| 3535-2 | Number of units transfused: Plasma: Apheresis: Riboflavin-treated |
| 3523-8 | Number of units transfused: Plasma: Whole blood-derived: Psoralen-treated |
| 3526-1 | Number of units transfused: Plasma: Whole blood-derived: Riboflavin-treated |
| 3423-1 | Number of units transfused: Platelets: Apheresis: Irradiated |
| 3427-2 | Number of units transfused: Platelets: Apheresis: Irradiated or leukocyte-reduced |
| 3425-6 | Number of units transfused: Platelets: Apheresis: Leukocyte-reduced |
| 3491-8 | Number of units transfused: Platelets: Apheresis: Not irradiated or leukocyte-reduced |
| 3514-7 | Number of units transfused: Platelets: Apheresis: Psoralen-treated |
| 3568-3 | Number of units transfused: Platelets: Apheresis: Psoralen-treated and in plasma |
| 3571-7 | Number of units transfused: Platelets: Apheresis: Psoralen-treated and in platelet additive solution |
| 3517-0 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated |
| 3574-1 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in plasma |
| 3577-4 | Number of units transfused: Platelets: Apheresis: Riboflavin-treated and in platelet additive solution |
| 3418-1 | Number of units transfused: Platelets: Whole blood-derived: Irradiated |
| 3420-7 | Number of units transfused: Platelets: Whole blood-derived: Irradiated and leukocyte-reduced |
| 3419-9 | Number of units transfused: Platelets: Whole blood-derived: Leukocyte-reduced |
| 3485-0 | Number of units transfused: Platelets: Whole blood-derived: Not irradiated or leukocyte-reduced |
| 3505-5 | Number of units transfused: Platelets: Whole blood-derived: Psoralen-treated |
| 3508-9 | Number of units transfused: Platelets: Whole blood-derived: Riboflavin-treated |
| 3411-6 | Number of units transfused: Red Blood Cells: Apheresis: Irradiated |
| 3415-7 | Number of units transfused: Red Blood Cells: Apheresis: Irradiated or leukocyte-reduced |
| 3413-2 | Number of units transfused: Red Blood Cells: Apheresis: Leukocyte-reduced |
| 3478-5 | Number of units transfused: Red Blood Cells: Apheresis: Not irradiated or leukocyte-reduced |
| 3559-2 | Number of units transfused: Red Blood Cells: Apheresis: Riboflavin-treated |
| 3556-8 | Number of units transfused: Red Blood Cells: Apheresis: S-303-treated |
| 3403-3 | Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated |
| 3407-4 | Number of units transfused: Red Blood Cells: Whole blood-derived: Irradiated and leukocyte-reduced |
| 3405-8 | Number of units transfused: Red Blood Cells: Whole blood-derived: Leukocyte-reduced |
| 3471-0 | Number of units transfused: Red Blood Cells: Whole blood-derived: Not irradiated or leukocyte-reduced |
| 3550-1 | Number of units transfused: Red Blood Cells: Whole blood-derived: Riboflavin-treated |
| 3547-7 | Number of units transfused: Red Blood Cells: Whole blood-derived: S-303-treated |
| 1853-1 | Number of urinary catheter days |
| 1852-3 | Number of ventilator days |
| 3005-6 | Nursing Home/Skilled Nursing Facility |
| 3056-9 | Observed or suspected patient injection into vascular line(s) within the BSI infection window |
| 1909-1 | Occult or gross blood in stools (with no rectal fissure) |
| 2202-0 | On admission and on discharge/transfer |
| 2201-2 | On admission only |
| 1930-7 | One positive culture with <=100,000 cfu/ml of a single uropathogen in patient being treated with an effective antimicrobial agent for UTI |
| 2403-4 | One positive culture with >=1,000 cfu/ml and <100,000 cfu/ml with no more than 2 species of microorganisms |
| 1927-3 | One positive culture with >=100,000 cfu/ml with no more than 2 species of microorganisms |
| 2302-8 | Only patients with no prior documentation of colonization or infection |
| 2129-5 | Open reduction of fracture |
| 1616-2 | Oral cavity infection (mouth, tongue, or gums) |
| 1650-1 | Order for prophylactic intravenous antibiotic not administered on time |
| 1640-2 | Organ/space |
| 1946-3 | Organism(s) identified from pleural fluid |
| 1817-6 | oritavancin |
| 2369-7 | Other contract personnel |
| 1905-9 | Other evidence of infection found |
| 1614-7 | Other infections of lower respiratory tract, other than pneumonia |
| 1617-0 | Other infections of the male or female reproductive tract (epididymis, testes, prostate, vagina, ovaries, uterus, or other deep pelvic tissues, excluding endometritis or vaginal cuff infections) |
| 1618-8 | Other infections of the urinary tract (kidney, ureter, bladder, urethra, or tissue surrounding the retroperitoneal or perinephric space) |
| 3006-4 | Other inpatient healthcare setting (e.g., Acute Care Hospital, LTAC, Rehabilitation, etc.) |
| 2104-8 | Other operations |
| 1941-4 | Other positive laboratory tests |
| 1906-7 | Other signs and symptoms |
| 2407-5 | Other than primary |
| 2130-3 | Ovarian surgery |
| 2054-5 | Oxacillinase-48-like |
| 2131-1 | Pacemaker surgery |
| 2517-1 | Pain not otherwise specified |
| 1960-4 | Pain or tenderness |
| 1312-8 | Passive surgical site infection (SSI) detection method |
| 3004-9 | Patient discharged from another facility in the past 4 weeks |
| 6132-5 | Patient has a documented/known allergy/reaction to chlorhexidine gluconate-based products that would preclude its use |
| 6131-7 | Patient is less than 2 months of age – chlorhexidine gluconate is to be used with caution in patients less than 2 months of age |
| 2342-6 | Patient on airway pressure release ventilation (APRV) or a related mode of mechanical ventilation at the time of VAE |
| 1326-8 | Patient or caregiver contacts facility to report |
| 1654-3 | Patient or family member |
| 1327-6 | Patient returns to outpatient facility for follow-up |
| 2041-2 | PCR: Imipenemase |
| 2039-6 | PCR: Klebsiella pneumoniae carbapenemase |
| 2040-4 | PCR: New Delhi metallo-beta-lactamase |
| 2043-8 | PCR: Oxacillinase-48 like |
| 2042-0 | PCR: Verona integron-encoded metallo-beta-lactamase |
| 2213-7 | Performer was a member of PICC/IV team |
| 3163-3 | Performs direct patient care |
| 3060-1 | Peripheral intravenous or midline catheter |
| 2132-9 | Peripheral vascular bypass surgery |
| 3115-3 | Peripherally inserted central catheter (PICC) |
| 1970-3 | Periprosthetic joint infection |
| 1003-3 | Permanent central line |
| 3007-2 | Personal residence/residential care |
| 4101-2 | Physician assistant |
| 1963-8 | Physician diagnosis of this event type |
| 1962-0 | Physician institutes appropriate antimicrobial therapy |
| 2212-9 | PICC team |
| 1926-5 | Pneumatoceles (in <=1 year old) |
| 1626-1 | Pneumonia 1 (PNU1) |
| 1631-1 | Pneumonia 2 (PNU2) |
| 1632-9 | Pneumonia 3 (PNU3) |
| 1955-4 | Positive blood culture |
| 1952-1 | Positive culture |
| 1966-1 | Positive culture from >=2 separate tissue or fluid samples from affected joint |
| 1953-9 | Positive culture of pathogen |
| 1954-7 | Positive culture of skin contaminant |
| 1948-9 | Positive culture of virus or Chlamydia |
| 1936-4 | Positive culture or microimmunofluorescence of Legionella species |
| 1934-9 | Positive detection of viral antigen or antibody |
| 1928-1 | Positive dipstick for leukocyte esterase or nitrate |
| 1943-0 | Positive Gram stain when culture is negative or not done |
| 1950-5 | Positive microimmunofluorescence test for Chlamydia |
| 1949-7 | Positive PCR for Chlamydia or Mycoplasma |
| 1947-1 | Positive quantitative culture from lower respiratory tract (LRT) specimen |
| 2345-0 | Possible ventilator-associated pneumonia (PVAP) |
| 1323-5 | Post-discharge patient letter |
| 1324-3 | Post-discharge patient phone call |
| 1322-7 | Post-discharge surgeon survey |
| 1505-7 | Post-discharge surveillance |
| 2406-7 | Primary |
| 2133-7 | Prostate surgery |
| 3059-3 | Pus present at vascular specimen collection site and matching organism identified in blood and from site-specific specimen(s) |
| 2305-1 | Pus, redness, or increased swelling |
| 1921-6 | Rales or bronchial breath sounds |
| 2518-9 | Rash not otherwise specified |
| 1517-2 | Readmission to facility other than where procedure was performed |
| 1516-4 | Readmission to facility where procedure was performed |
| 2504-9 | Received non-irradiated blood in the 2 months preceding the reaction |
| 3071-8 | Recognized pathogen from cerebrospinal fluid specimen |
| 1951-3 | Recognized pathogen from one or more blood cultures |
| 3104-7 | Recorder was performer |
| 2134-5 | Rectal surgery |
| 2135-2 | Refusion of spine |
| 2404-2 | Removed within 48 hours prior |
| 1329-2 | Report from another facility (inpatient, health department, emergency department, etc.) |
| 1341-7 | Report No Events: Antimicrobial Resistance (AR) |
| 3052-8 | Report No Events: Dialysis: intravenous antimicrobial start |
| 3053-6 | Report No Events: Dialysis: positive blood culture |
| 3054-4 | Report No Events: Dialysis: pus, redness, or increased swelling at vascular access site |
| 3011-4 | Report No Events: ICU: CAUTI |
| 3010-6 | Report No Events: ICU: CLABSI |
| 1338-3 | Report No Events: ICU: PedVAE |
| 3013-0 | Report No Events: ICU: PedVAP |
| 3012-2 | Report No Events: ICU: VAE |
| 3050-2 | Report No Events: Infection Surveillance: C. difficile |
| 3035-3 | Report No Events: Infection Surveillance: CephR Klebsiella |
| 3038-7 | Report No Events: Infection Surveillance: CRE-E. coli |
| 3041-1 | Report No Events: Infection Surveillance: CRE-Enterobacter |
| 3044-5 | Report No Events: Infection Surveillance: CRE-Klebsiella |
| 3047-8 | Report No Events: Infection Surveillance: MDR-Acinetobacter |
| 3029-6 | Report No Events: Infection Surveillance: MRSA |
| 1306-0 | Report No Events: Infection Surveillance: MSSA |
| 3032-0 | Report No Events: Infection Surveillance: VRE |
| 3051-0 | Report No Events: LabID Event (All specimens): C. difficile |
| 3036-1 | Report No Events: LabID Event (All specimens): CephR Klebsiella |
| 3039-5 | Report No Events: LabID Event (All specimens): CRE-E. coli |
| 3042-9 | Report No Events: LabID Event (All specimens): CRE-Enterobacter |
| 3045-2 | Report No Events: LabID Event (All specimens): CRE-Klebsiella |
| 3048-6 | Report No Events: LabID Event (All specimens): MDR-Acinetobacter |
| 3030-4 | Report No Events: LabID Event (All specimens): MRSA |
| 1307-8 | Report No Events: LabID Event (All specimens): MSSA |
| 3033-8 | Report No Events: LabID Event (All specimens): VRE |
| 3037-9 | Report No Events: LabID Event (Blood specimens only): CephR Klebsiella |
| 3040-3 | Report No Events: LabID Event (Blood specimens only): CRE-E. coli |
| 3043-7 | Report No Events: LabID Event (Blood specimens only): CRE-Enterobacter |
| 3046-0 | Report No Events: LabID Event (Blood specimens only): CRE-Klebsiella |
| 3049-4 | Report No Events: LabID Event (Blood specimens only): MDR-Acinetobacter |
| 3031-2 | Report No Events: LabID Event (Blood specimens only): MRSA |
| 1308-6 | Report No Events: LabID Event (Blood specimens only): MSSA |
| 3034-6 | Report No Events: LabID Event (Blood specimens only): VRE |
| 3016-3 | Report No Events: NICU: CLABSI: 1001-1500 grams |
| 3017-1 | Report No Events: NICU: CLABSI: 1501-2500 grams |
| 3015-5 | Report No Events: NICU: CLABSI: 751-1000 grams |
| 3018-9 | Report No Events: NICU: CLABSI: over 2500 grams |
| 3014-8 | Report No Events: NICU: CLABSI: under 750 grams |
| 1316-9 | Report No Events: NICU: PedVAE: birth weight 1001-1500 grams |
| 1317-7 | Report No Events: NICU: PedVAE: birth weight 1501-2500 grams |
| 1314-4 | Report No Events: NICU: PedVAE: birth weight 751-1000 grams |
| 1318-5 | Report No Events: NICU: PedVAE: birth weight over 2500 grams |
| 1313-6 | Report No Events: NICU: PedVAE: birth weight under 750 grams |
| 1319-3 | Report No Events: NICU: PedVAE: Extremely preterm (<28 weeks) |
| 1331-8 | Report No Events: NICU: PedVAE: Moderate to late preterm (32 to <37 weeks) |
| 1332-6 | Report No Events: NICU: PedVAE: Term (>=37 weeks) |
| 1330-0 | Report No Events: NICU: PedVAE: Very preterm (28 to <32 weeks) |
| 3021-3 | Report No Events: NICU: PedVAP: 1001-1500 grams |
| 3022-1 | Report No Events: NICU: PedVAP: 1501-2500 grams |
| 3020-5 | Report No Events: NICU: PedVAP: 751-1000 grams |
| 3023-9 | Report No Events: NICU: PedVAP: over 2500 grams |
| 3019-7 | Report No Events: NICU: PedVAP: under 750 grams |
| 1340-9 | Report No Events: Same Day Outcome Measures |
| 3026-2 | Report No Events: SCA: CAUTI |
| 3025-4 | Report No Events: SCA: PCLAB |
| 1339-1 | Report No Events: SCA: PedVAE |
| 3028-8 | Report No Events: SCA: PedVAP |
| 3024-7 | Report No Events: SCA: TCLAB |
| 3027-0 | Report No Events: SCA: VAE |
| 1796-2 | Reproductive tract infection |
| 1370-6 | Resident admissions |
| 1369-8 | Resident days |
| 1375-5 | Resident on antibiotic therapy for this specific organism at the time of transfer |
| 1374-8 | Resident transferred from acute care facility in past 4 weeks |
| 1321-9 | Review of patient’s medical record |
| 1239-3 | Revision associated with prior infection at index joint |
| 1653-5 | Routine follow-up at outpatient facility |
| 3192-2 | Seasons immunized |
| 3111-2 | Secondary bloodstream infection |
| 2102-2 | Shunt for dialysis |
| 1968-7 | Sinus tract |
| 2321-8 | Site of non-tunneled central line, dialysis |
| 2322-6 | Site of tunneled central line, dialysis |
| 2136-0 | Small bowel surgery |
| 1677-4 | Soft tissue, muscle, lymph node, or salivary gland infection |
| 3114-6 | Solution(s) had dried |
| 1619-6 | Spinal abscess without meningitis |
| 2137-8 | Spinal fusion |
| 2138-6 | Spleen surgery |
| 6113-5 | Sterile gloves |
| 6111-9 | Sterile gown |
| 1884-6 | Summary data reporting active surveillance testing (AST) |
| 2410-9 | Summary data reporting antimicrobial resistance patterns at a facility |
| 1887-9 | Summary data reporting antimicrobial usage |
| 1879-6 | Summary data reporting catheter and ventilator use in a ICU/other |
| 1881-2 | Summary data reporting catheter and ventilator use in a NICU |
| 1880-4 | Summary data reporting catheter and ventilator use in a SCA |
| 1891-1 | Summary data reporting MDRO and CDI LabID Event for LTCF |
| 1657-6 | Summary data reporting outpatient procedure component events at a facility |
| 2316-8 | Summary data reporting vascular access types for chronic hemodialysis patients |
| 1620-4 | Superficial incisional primary surgical site infection (SSI) |
| 1621-2 | Superficial incisional secondary surgical site infection (SSI) |
| 1328-4 | Surgeon contacts facility to report |
| 1238-5 | Surgical site infection (SSI) detected using the NHSN ICD-code based admit and readmit SSI surveillance toolkit |
| 1625-3 | Symptomatic UTI (SUTI) |
| 1816-8 | tedizolid |
| 2348-1 | Temperature >38°C or <36°C |
| 1005-8 | Temporary central line |
| 1337-5 | Term (>=37 weeks) |
| 2139-4 | Thoracic surgery |
| 2140-2 | Thyroid and/or parathyroid surgery |
| 1870-5 | Timing of active surveillance testing (AST) |
| 5105-2 | To address a new indication for a central line |
| 5107-8 | To replace an existing central line where infection was suspected |
| 5106-0 | To replace an existing, malfunctioning central line |
| 3538-6 | Total crossmatch procedures |
| 1644-4 | Total number of admissions with a primary CPT code in this procedure category |
| 3432-2 | Total number of aliquots transfused: Plasma: Apheresis |
| 3530-3 | Total number of aliquots transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated |
| 3430-6 | Total number of aliquots transfused: Plasma: Whole blood-derived |
| 3521-2 | Total number of aliquots transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated |
| 3422-3 | Total number of aliquots transfused: Platelets: Apheresis |
| 3512-1 | Total number of aliquots transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated |
| 3410-8 | Total number of aliquots transfused: Red Blood Cells: Apheresis |
| 3554-3 | Total number of aliquots transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated |
| 3402-5 | Total number of aliquots transfused: Red Blood Cells: Whole blood-derived |
| 3545-1 | Total number of aliquots transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated |
| 3468-6 | Total number of aliquots transfused: Whole Blood |
| 3501-4 | Total number of discards: Cryoprecipitate |
| 3563-4 | Total number of discards: Cryoprecipitate: Psoralen- and Riboflavin-treated |
| 3500-6 | Total number of discards: Plasma: Apheresis |
| 3531-1 | Total number of discards: Plasma: Apheresis: Psoralen- and Riboflavin-treated |
| 3497-5 | Total number of discards: Plasma: Whole blood-derived |
| 3522-0 | Total number of discards: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated |
| 3490-0 | Total number of discards: Platelets: Apheresis |
| 3513-9 | Total number of discards: Platelets: Apheresis: Psoralen- and Riboflavin-treated |
| 3484-3 | Total number of discards: Platelets: Whole blood-derived |
| 3504-8 | Total number of discards: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated |
| 3477-7 | Total number of discards: Red Blood Cells: Apheresis |
| 3555-0 | Total number of discards: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated |
| 3470-2 | Total number of discards: Red Blood Cells: Whole blood-derived |
| 3546-9 | Total number of discards: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated |
| 3469-4 | Total number of discards: Whole Blood |
| 3433-0 | Total number of units transfused: Cryoprecipitate |
| 3562-6 | Total number of units transfused: Cryoprecipitate: Psoralen- and Riboflavin-treated |
| 3431-4 | Total number of units transfused: Plasma: Apheresis |
| 3529-5 | Total number of units transfused: Plasma: Apheresis: Psoralen- and Riboflavin-treated |
| 3429-8 | Total number of units transfused: Plasma: Whole blood-derived |
| 3520-4 | Total number of units transfused: Plasma: Whole blood-derived: Psoralen- and Riboflavin-treated |
| 3421-5 | Total number of units transfused: Platelets: Apheresis |
| 3511-3 | Total number of units transfused: Platelets: Apheresis: Psoralen- and Riboflavin-treated |
| 3417-3 | Total number of units transfused: Platelets: Whole blood-derived |
| 3502-2 | Total number of units transfused: Platelets: Whole blood-derived: Psoralen- and Riboflavin-treated |
| 3409-0 | Total number of units transfused: Red Blood Cells: Apheresis |
| 3553-5 | Total number of units transfused: Red Blood Cells: Apheresis: S-303- and Riboflavin-treated |
| 3401-7 | Total number of units transfused: Red Blood Cells: Whole blood-derived |
| 3544-4 | Total number of units transfused: Red Blood Cells: Whole blood-derived: S-303- and Riboflavin-treated |
| 3467-8 | Total number of units transfused: Whole Blood |
| 3539-4 | Total patients transfused |
| 2036-2 | Toxigenic culture |
| 2304-4 | Transient patient |
| 1117-1 | Tunneled (dialysis) |
| 1118-9 | Tunneled (other than dialysis) |
| 1116-3 | Umbilical |
| 1622-0 | Upper respiratory tract infection, pharyngitis, laryngitis, epiglottitis |
| 3191-4 | Urinary catheter present |
| 1972-9 | Urine not tested for white blood cells |
| 1624-6 | Vaginal cuff infection |
| 2141-0 | Vaginal hysterectomy |
| 2319-2 | Vascular access |
| 2323-4 | Vascular site fistula |
| 2324-2 | Vascular site graft |
| 2343-4 | Ventilator-associated condition (VAC) |
| 2340-3 | Ventilator-associated event (VAE) |
| 2142-8 | Ventricular shunt |
| 2053-7 | Verona integron-encoded metallo-beta-lactamase |
| 1606-3 | Vertebral disc space infection |
| 1335-9 | Very preterm (28 to <32 weeks) |
| 1922-4 | Wheezing, rales or rhonchi |
| 2331-7 | Where was the positive blood culture collected |
| 2349-9 | White blood cell count >=12,000 or <=4,000 cells/mm3 |
| 1958-8 | Worsening gas exchange |
| 2320-0 | Wound (not related to vascular access) with pus or increased redness |
| 1649-3 | Wrong implant |
| 1648-5 | Wrong patient |
| 1647-7 | Wrong side |
| 1646-9 | Wrong site |
